Faeth Therapeutics (4070) Price & Analysis

1 Followers

4070 Stock Chart & Stats

€6.00

€0.00(0.00%)

At close: Jul 27 4:00 PM EDT

€6.00

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€5.70 - €6.00

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€608.90M

Enterprise Value€167.54

Total Cash (Recent Filing)€186.44M

Total Debt (Recent Filing)€592.00K

Price to Earnings (P/E)―

Beta1.35

Next Earnings

Nov 10, 2026

EPS Estimate

-1.43

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-146.83

Shares Outstanding25,778,753

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)0.72

Price to Sales (P/S)0.00

P/FCF Ratio-0.66

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€48.16

Price Target Upside702.64% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)-44.74

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Strong Balance SheetVery low debt reduces near-term solvency risk and preserves financial flexibility to fund clinical programs or license deals over the next several quarters. A low-leverage profile supports strategic optionality (partnering, M&A, or targeted financings) without heavy interest burden.

Major Strategic Financing And CombinationThe $200M PIPE and combination with Sensei materially bolsters capital to advance multiple clinical programs and test the multi-nodal hypothesis. This structural funding reduces immediate financing pressure, enables larger trials and data readouts, and materially de-risks near-term development timelines.

Performance-Based Equity AlignmentA one-time performance option plan ties management and employee pay to sustained shareholder value or change-of-control outcomes. Such strict vesting conditions promote long-term focus on execution, disciplined capital allocation, and strategic outcomes rather than short-term share-price moves.

Bears Say

No Revenue / Persistent LossesFaeth remains a pre-commercial biotech with no revenue and sustained net losses, meaning core operations are not self-sustaining. Over a multi-quarter horizon this keeps the company dependent on trial success and external funding, increasing execution risk if clinical setbacks occur.

Ongoing Negative Cash FlowConsistent negative operating and free cash flow indicate the company cannot internally finance development. Even with improving outflows, continued cash burn necessitates further capital events that can dilute shareholders or shift strategic priorities if data timelines slip.

Dilution Risk From Equity Programs And ConversionsAn established at-the-market program and recent preferred-to-common conversion materially enlarged the share base. Structural reliance on equity raises creates ongoing dilution risk and potential shareholder dilution over the coming quarters if additional financings are required to sustain development.

Faeth Therapeutics News

Faeth Therapeutics management to meet with BTIG

Meeting to be held in Baltimore/Washington, DC on August 10 hosted by BTIG. Published first on TheFly –...

15h ago

FTH

Faeth Therapeutics initiated with a Buy at JonesResearch

JonesResearch analyst Boris Peaker initiated coverage of Faeth Therapeutics (FTH) with a Buy rating and $55 price target...

20h ago

FTH

Faeth Therapeutics reports Q2 EPS ($2.84) vs ($3.91) last year

“Our combination with Sensei Biotherapeutics marked an important milestone in the history of Faeth Therapeutics (FTH),” said Anand...

20h ago

FTH

Roblox downgraded, Quanta Services upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

5d ago

BSX

Faeth Therapeutics initiated with an Outperform at Raymond James

Raymond James initiated coverage of Faeth Therapeutics (FTH) with an Outperform rating and $56 price target The firm’s...

5d ago

FTH

Faeth Therapeutics initiated with an Outperform at Oppenheimer

Oppenheimer initiated coverage of Faeth Therapeutics (FTH) with an Outperform rating and $60 price target Revtorpyk’s approval in...

8d ago

FTH

Faeth Therapeutics initiated with an Outperform at Citizens

Citizens initiated coverage of Faeth Therapeutics (FTH) with an Outperform rating and $51 price target The company is...

16d ago

FTH

Faeth Therapeutics, Inc trading resumes

15:41 EDT Faeth Therapeutics (FTH), Inc trading resumes Published first on TheFly – the ultimate source for real-time,...

20d ago

FTH

Faeth Therapeutics, Inc trading halted, volatility trading pause

15:31 EDT Faeth Therapeutics (FTH), Inc trading halted, volatility trading pause Published first on TheFly – the ultimate...

21d ago

FTH

Faeth Therapeutics Adopts Performance-Based Stock Option Plan

Faeth Therapeutics ( ($FTH) ) has issued an announcement. On July 21, 2026, Faeth Therapeutics’ board approved one-time...

12d ago

FTH

Faeth’s PIKTOR Trial Targets Advanced Breast Cancer With a New Combo Approach

Faeth Therapeutics, Inc. ($FTH) announced an update on their ongoing clinical study. Faeth Therapeutics, Inc. is running an...

1M ago

FTH

Faeth Therapeutics initiated with an Outperform at Baird

Baird analyst Jack Allen initiated coverage of Faeth Therapeutics (FTH) with an Outperform rating and $57 price target...

1M ago

FTH

Faeth Therapeutics Launches New At-the-Market Equity Program

The latest update is out from Faeth Therapeutics ( ($FTH) ). On June 18, 2026, Faeth Therapeutics, Inc....

2M ago

FTH

Faeth Therapeutics Rebrands, Relocates and Overhauls Leadership

Sensei Biotherapeutics ( ($SNSE) ) has issued an update. On June 10, 2026, Faeth Therapeutics, formerly Sensei Biotherapeutics,...

2M ago

SNSE

4070 FAQ

What was Faeth Therapeutics’s price range in the past 12 months?

Faeth Therapeutics lowest stock price was €5.70 and its highest was €6.00 in the past 12 months.

What is Faeth Therapeutics’s market cap?

Faeth Therapeutics’s market cap is €608.90M.

When is Faeth Therapeutics’s upcoming earnings report date?

Faeth Therapeutics’s upcoming earnings report date is Nov 10, 2026 which is in 97 days.

How were Faeth Therapeutics’s earnings last quarter?

Faeth Therapeutics released its earnings results on Aug 04, 2026. The company reported -€2.463 earnings per share for the quarter, missing the consensus estimate of -€2.286 by -€0.177.

Is Faeth Therapeutics overvalued?

According to Wall Street analysts Faeth Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Faeth Therapeutics pay dividends?

Faeth Therapeutics does not currently pay dividends.

What is Faeth Therapeutics’s EPS estimate?

Faeth Therapeutics’s EPS estimate is -1.43.

How many shares outstanding does Faeth Therapeutics have?

Faeth Therapeutics has 25,778,753 shares outstanding.

What happened to Faeth Therapeutics’s price movement after its last earnings report?

Faeth Therapeutics reported an EPS of -€2.463 in its last earnings report, missing expectations of -€2.286. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Faeth Therapeutics?

Currently, no hedge funds are holding shares in DE:4070

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Faeth Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

436.62%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Faeth Therapeutics

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]

Faeth Therapeutics (4070) Earnings & Revenues

Historic Earnings Reports

4070 Stock 12 Month Forecast

Average Price Target

€48.16

▲(702.64% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"€5","17":"€17","29":"€29","41":"€41","53":"€53"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":52.1153628,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€52.12</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48.15845562444444,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€48.16</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":43.429469,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€43.43</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,17,29,41,53],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6,9.5473356,13.0946712,16.642006799999997,20.1893424,23.736677999999998,27.284013599999998,30.8313492,34.3786848,37.9260204,41.473355999999995,45.0206916,48.568027199999996,{"y":52.1153628,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6,9.242958124957266,12.48591624991453,15.728874374871793,18.97183249982906,22.214790624786325,25.457748749743587,28.700706874700852,31.943664999658118,35.18662312461538,38.42958124957265,41.67253937452991,44.915497499487174,{"y":48.15845562444444,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6,8.879189923076922,11.758379846153845,14.637569769230769,17.51675969230769,20.395949615384612,23.275139538461538,26.15432946153846,29.03351938461538,31.912709307692303,34.791899230769225,37.671089153846154,40.550279076923076,{"y":43.429469,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >